X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs TORRENT PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON TORRENT PHARMA BIOCON /
TORRENT PHARMA
 
P/E (TTM) x 40.5 37.6 107.7% View Chart
P/BV x 7.0 6.6 106.0% View Chart
Dividend Yield % 0.2 0.8 21.3%  

Financials

 BIOCON    TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
TORRENT PHARMA
Mar-18
BIOCON /
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1881,550 76.6%   
Low Rs3051,144 26.7%   
Sales per share (Unadj.) Rs68.7354.7 19.4%  
Earnings per share (Unadj.) Rs7.640.1 18.8%  
Cash flow per share (Unadj.) Rs14.064.2 21.8%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.11.0 12.9%  
Book value per share (Unadj.) Rs86.3273.1 31.6%  
Shares outstanding (eoy) m600.00169.22 354.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.8 286.1%   
Avg P/E ratio x98.933.6 294.1%  
P/CF ratio (eoy) x53.421.0 254.8%  
Price / Book Value ratio x8.64.9 175.3%  
Dividend payout %13.234.9 37.9%   
Avg Mkt Cap Rs m447,900227,897 196.5%   
No. of employees `0006.114.7 41.8%   
Total wages/salary Rs m9,31111,353 82.0%   
Avg. sales/employee Rs Th6,705.84,083.0 164.2%   
Avg. wages/employee Rs Th1,514.2772.3 196.1%   
Avg. net profit/employee Rs Th736.9461.3 159.7%   
INCOME DATA
Net Sales Rs m41,23460,021 68.7%  
Other income Rs m2,0622,988 69.0%   
Total revenues Rs m43,29663,009 68.7%   
Gross profit Rs m8,29113,493 61.4%  
Depreciation Rs m3,8514,086 94.2%   
Interest Rs m6153,085 19.9%   
Profit before tax Rs m5,8879,310 63.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,529 62.0%   
Profit after tax Rs m4,5316,781 66.8%  
Gross profit margin %20.122.5 89.4%  
Effective tax rate %26.727.2 98.1%   
Net profit margin %11.011.3 97.3%  
BALANCE SHEET DATA
Current assets Rs m41,48652,623 78.8%   
Current liabilities Rs m21,41352,022 41.2%   
Net working cap to sales %48.71.0 4,857.6%  
Current ratio x1.91.0 191.5%  
Inventory Days Days64120 53.5%  
Debtors Days Days9476 123.5%  
Net fixed assets Rs m50,66185,016 59.6%   
Share capital Rs m3,000846 354.5%   
"Free" reserves Rs m48,80845,376 107.6%   
Net worth Rs m51,80846,222 112.1%   
Long term debt Rs m17,89841,115 43.5%   
Total assets Rs m99,897142,432 70.1%  
Interest coverage x10.64.0 263.1%   
Debt to equity ratio x0.30.9 38.8%  
Sales to assets ratio x0.40.4 98.0%   
Return on assets %5.26.9 74.4%  
Return on equity %8.714.7 59.6%  
Return on capital %9.614.2 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05814,580 82.7%   
Fx outflow Rs m7,3483,600 204.1%   
Net fx Rs m4,71010,980 42.9%   
CASH FLOW
From Operations Rs m6,6218,942 74.0%  
From Investments Rs m-6,840-47,070 14.5%  
From Financial Activity Rs m-2,39734,174 -7.0%  
Net Cashflow Rs m-2,612-3,655 71.5%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 495 Points, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a negative note and ended the day deep in red after a volatile day of trading.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 22, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS